跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Johnson & Johnson Pharmaceutical Research & Development LLC

首页临床试验发起方与机构Johnson & Johnson Pharmaceutical Research & Development LLC

Johnson & Johnson Pharmaceutical Research & Development LLC

ACTIVE

New Jersey, 美国Subsidiary

隶属于强生

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

9

0 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

3 期

9

100.0%

试验状态分布

已完成

9

100.0%

相关临床试验

该机构主办的试验（9）

This study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar) control.

Dec 2010360 名受试者

This study is to check the efficacy, safety, and tolerability of JNJ-28431754 compared with glimepiride in patients with type 2 diabetes

Jun 20101281 名受试者

A Randomised Double-Blind Placebo-Controlled Multicenter Study with Extension to Evaluate the Efficacy Safety and Tolerability of Canagliflozin in the Treatment of Subjects with Type 2 DiabetesMellitus Who Have Moderate Renal Impairment

Mar 2010272 名受试者

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients.

Jan 2010100 名受试者

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Oct 200915527 名受试者

This study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar) control.

360 名受试者

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

15527 名受试者

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients.

第 1 页，共 2 页

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验9
药物批准
资讯

返回机构列表